Corporate Earnings

Versus the second quarter, net income climbed 32% from $22 million, while revenues eased 6% from $497 million. AnnualizedReturn on Equitywas 3%, against 2% in the prior quarter and 18% a year earlier.

Revenue reached $410.1 million, up $55.5 million from $354.7 million a year earlier. Thrombectomy revenue rose 18.1% to $279.2 million, which the company attributed mainly to higher U.S.Volumefrom new products and further uptake of existing ones. Embolization and access revenue increased 10.8% to $131.0 …

The number of ads served rose 17%, while the price of ads fell 4%. Global average revenue per user was $1.80, up 1%, and average monthly active users grew 10%, so most of the growth came from a larger audience rather than higher monetization …

Medical device sales came in at $17.4 million, a 21% increase from $14.4 million, lifting their share of the total to 85% from 77%. Orthopedic revenue grew 16% to $12.8 million, chiefly because of the next generation handpiece sold to the largest customer. CMF …

Net productRevenuewas $275.9 million versus $131.0 million, driven by a $162.3 million increase in Sephience, which treats phenylketonuria.Royaltyrevenue rose 15% to $81.7 million on higher Evrysdi sales, while collaboration and license revenue fell to $0.2 million from $9.3 million.

Net sales reached $544.5 million, up 10% from $493.8 million. Selling price and product mix contributed about 7%, reflecting pricing moves that offset higher raw material costs and index-based customer contracts, while volumes added about 3% on newBusinesswins across all segments.

Advertising revenue increased $297.7 million, or 54%. The filing says the gain came mainly from pricing, with the price of ads up about 34%, and to a lesser extent from ad impressions delivered, which rose about 15%. U.S. revenue grew 50% and rest of …